Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Short-term Investments (2016 - 2026)

Insight Molecular Diagnostics' Short-term Investments history spans 6 years, with the latest figure at $729000.0 for Q4 2025.

  • On a quarterly basis, Short-term Investments changed N/A to $729000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $729000.0, a N/A change, with the full-year FY2025 number at $729000.0, changed N/A from a year prior.
  • Short-term Investments hit $729000.0 in Q4 2025 for Insight Molecular Diagnostics, roughly flat from $729000.0 in the prior quarter.
  • Over the last five years, Short-term Investments for IMDX hit a ceiling of $1.1 million in Q2 2021 and a floor of $419000.0 in Q3 2022.
  • Historically, Short-term Investments has averaged $671769.2 across 4 years, with a median of $579000.0 in 2022.
  • Biggest five-year swings in Short-term Investments: soared 211.44% in 2021 and later tumbled 54.6% in 2022.
  • Tracing IMDX's Short-term Investments over 4 years: stood at $904000.0 in 2021, then tumbled by 52.1% to $433000.0 in 2022, then increased by 1.85% to $441000.0 in 2023, then skyrocketed by 65.31% to $729000.0 in 2025.
  • Business Quant data shows Short-term Investments for IMDX at $729000.0 in Q4 2025, $729000.0 in Q3 2025, and $441000.0 in Q3 2023.